浙江医学
浙江醫學
절강의학
ZHEJIANG MEDICAL JOURNAL
2013年
10期
885-888
,共4页
陈丽羽%汪丽菁%王立平%时开元%刘俊平%金鑫焱%钱超文
陳麗羽%汪麗菁%王立平%時開元%劉俊平%金鑫焱%錢超文
진려우%왕려정%왕립평%시개원%류준평%금흠염%전초문
肝肿瘤%门静脉%射频消融术
肝腫瘤%門靜脈%射頻消融術
간종류%문정맥%사빈소융술
Liver neoplasms%Portal vein%Radiofrequency ablation
目的探讨经皮冷循环射频消融治疗大血管旁肝脏恶性肿瘤的安全性和有效性.方法经皮冷循环消融治疗肝脏恶性肿瘤患者297例共358枚结节,其中存在大血管旁结节的患者77例(79枚,血管旁组),分别将患者的临床资料、并发症发生情况、治疗后无瘤生存率及结节的局部残留复发情况与非血管旁的患者220例(279枚,非血管旁组)进行比较.结果两组患者均未发生射频相关死亡,血管旁组和非血管旁组患者的严重并发症发生率分别为3.9%与2.7%(P>0.05).1、2、3年无瘤生存率血管旁组分别为54.3%、48.8%、35.5%,非血管旁组为59.7%、35.4%、30.7%(P>0.05).血管旁组和非血管旁组结节的局部复发率分别为22.8%、16.1%(P>0.05).结论对于血管旁的肝恶性肿瘤,射频消融是一个安全而有效的治疗措施.
目的探討經皮冷循環射頻消融治療大血管徬肝髒噁性腫瘤的安全性和有效性.方法經皮冷循環消融治療肝髒噁性腫瘤患者297例共358枚結節,其中存在大血管徬結節的患者77例(79枚,血管徬組),分彆將患者的臨床資料、併髮癥髮生情況、治療後無瘤生存率及結節的跼部殘留複髮情況與非血管徬的患者220例(279枚,非血管徬組)進行比較.結果兩組患者均未髮生射頻相關死亡,血管徬組和非血管徬組患者的嚴重併髮癥髮生率分彆為3.9%與2.7%(P>0.05).1、2、3年無瘤生存率血管徬組分彆為54.3%、48.8%、35.5%,非血管徬組為59.7%、35.4%、30.7%(P>0.05).血管徬組和非血管徬組結節的跼部複髮率分彆為22.8%、16.1%(P>0.05).結論對于血管徬的肝噁性腫瘤,射頻消融是一箇安全而有效的治療措施.
목적탐토경피랭순배사빈소융치료대혈관방간장악성종류적안전성화유효성.방법경피랭순배소융치료간장악성종류환자297례공358매결절,기중존재대혈관방결절적환자77례(79매,혈관방조),분별장환자적림상자료、병발증발생정황、치료후무류생존솔급결절적국부잔류복발정황여비혈관방적환자220례(279매,비혈관방조)진행비교.결과량조환자균미발생사빈상관사망,혈관방조화비혈관방조환자적엄중병발증발생솔분별위3.9%여2.7%(P>0.05).1、2、3년무류생존솔혈관방조분별위54.3%、48.8%、35.5%,비혈관방조위59.7%、35.4%、30.7%(P>0.05).혈관방조화비혈관방조결절적국부복발솔분별위22.8%、16.1%(P>0.05).결론대우혈관방적간악성종류,사빈소융시일개안전이유효적치료조시.
Objective To evaluate the safety and efficacy of percutaneous radiofrequency ablation (RFA) for perivascular malignant liver tumors. Methods Total 297 patients with hepatic malignant tumors (358 nodules) underwent RFA using an inter-nal y cooled electrode, among them 77 patients had 79 nodules, which were<5mm from the intrahepatic vessels and>3mm in diameter (perivascular group), and 220 patients had 279 nonperivascular nodules which were >5mm from large vessels(non-perivascular group). The clinical data and outcomes were compared between two groups. Results There were no treat-ment-related death and the complication rate was similar in two group (3.9%vs 2.7%, P>0.05). The disease-free 1-, 2-, and 3-year survival rates in perivascular group were 54.3%, 48.8%and 35.5%, respectively, and those in nonperivascular group were 59.7%, 35.4%and 30.7%, respectively(P>0.05). There were no significant differences between perivascular and nonperivascular groups in local recurrence rate (22.8%vs 16.1%, P>0.05). Conclusion RFA is a safe and effective for treatment of perivascular malignant liver tumors.